COVID-19危重症患者中急性呼吸窘迫综合征表型的患病率:一项前瞻性观察性研究
本研究为在英国两个ICU开展的前瞻性观察性研究,2020年3月17日至4月25日纳入39例COVID-19相关ARDS患者,基线采集人口学、临床和实验室数据,用新型即时检测分析血浆IL-6和可溶性TNFR1,并以IL-6、可溶性TNFR1和碳酸氢盐水平的简约回归分类模型计算高炎症表型概率。39例中17例(44%)在28天时死亡;高炎症表型患病率随概率截断值不同为4/39(10%)至8/39(21%),低于HARP-2试验中非COVID-19 ARDS的186/539(35%)。以约登指数截断值0.274分类时,高炎症表型8例中5例(63%)死亡,低炎症表型31例中12例(39%)死亡。与HARP-2匹配患者相比,本队列IL-6水平相似,可溶性TNFR1显著更低。作者结论认为COVID-19相关ARDS与更高全身炎症无关,其超额死亡不太可能由该简约模型描述的高炎症通路上调所致。
要点
- 英国两个ICU前瞻性纳入39例COVID-19相关ARDS患者,28天死亡率44%(17/39),死亡者较存活者年龄更大且PaO2/FiO2更低。
- 高炎症表型概率中位数仅0.03(IQR 0.01–0.2),按不同概率截断值高炎症表型患病率为4/39(10%)至8/39(21%),低于HARP-2非COVID-19 ARDS的186/539(35%)。
- 以约登指数截断值0.274分类,高炎症表型8例中5例(63%)死亡,低炎症表型31例中12例(39%)死亡。
- 与HARP-2匹配患者相比,COVID-19相关ARDS患者IL-6水平相似,可溶性TNFR1显著更低。
- 作者认为COVID-19相关ARDS的超额死亡不太可能由该简约模型描述的高炎症通路上调所致。
适用人群与场景
- 英国两个ICU收治的COVID-19相关ARDS患者,2020年3月17日至4月25日招募,共39例。
- 对照人群为既往英国多中心辛伐他汀随机对照试验(HARP-2)中非COVID-19所致ARDS患者。
诊断标准与关键阈值
- 高炎症表型概率由基于IL-6、可溶性TNFR1和碳酸氢盐水平的简约回归分类模型计算。
- 以约登指数截断值0.274将患者分类为高炎症或低炎症表型。
研究设计与关键结果
- 前瞻性观察性研究,英国两个ICU,纳入39例COVID-19相关ARDS患者;基线PaO2/FiO2中位数18 kPa(IQR 15–21),APACHE II评分中位数12(IQR 10–16)。
- 28天死亡17/39(44%);与存活者相比,死亡者年龄更大且PaO2/FiO2更低。
- 高炎症表型概率中位数0.03(IQR 0.01–0.2);按不同概率截断值,高炎症表型患病率为4/39(10%)至8/39(21%),低于HARP-2的186/539(35%)。
- 以约登指数截断值0.274分类,高炎症表型8例中5例(63%)死亡,低炎症表型31例中12例(39%)死亡。
- 与HARP-2匹配患者相比,本队列IL-6水平相似,可溶性TNFR1显著更低。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(探索性分析)。
- 作者结论:COVID-19相关ARDS与更高全身炎症无关,高炎症表型患病率低于历史非COVID-19 ARDS数据;COVID-19相关ARDS的超额死亡不太可能由该简约模型描述的高炎症通路上调所致。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,COVID-19相关ARDS的超额死亡不太可能由该简约模型描述的高炎症通路上调所致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In acute respiratory distress syndrome (ARDS) unrelated to COVID-19, two phenotypes, based on the severity of systemic inflammation (hyperinflammatory and hypoinflammatory), have been described. The hyperinflammatory phenotype is known to be associated with increased multiorgan failure and mortality. In this study, we aimed to identify these phenotypes in COVID-19-related ARDS.
METHODS: In this prospective observational study done at two UK intensive care units, we recruited patients with ARDS due to COVID-19. Demographic, clinical, and laboratory data were collected at baseline. Plasma samples were analysed for interleukin-6 (IL-6) and soluble tumour necrosis factor receptor superfamily member 1A (TNFR1) using a novel point-of-care assay. A parsimonious regression classifier model was used to calculate the probability for the hyperinflammatory phenotype in COVID-19 using IL-6, soluble TNFR1, and bicarbonate levels. Data from this cohort was compared with patients with ARDS due to causes other than COVID-19 recruited to a previous UK multicentre, randomised controlled trial of simvastatin (HARP-2).
FINDINGS: Between March 17 and April 25, 2020, 39 patients were recruited to the study. Median ratio of partial pressure of arterial oxygen to fractional concentration of oxygen in inspired air (PaO2/FiO2) was 18 kpa (IQR 15-21) and acute physiology and chronic health evaluation II score was 12 (10-16). 17 (44%) of 39 patients had died by day 28 of the study. Compared with survivors, patients who died were older and had lower PaO2/FiO2. The median probability for the hyperinflammatory phenotype was 0·03 (IQR 0·01-0·2). Depending on the probability cutoff used to assign class, the prevalence of the hyperinflammatory phenotype was between four (10%) and eight (21%) of 39, which is lower than the proportion of patients with the hyperinflammatory phenotype in HARP-2 (186 [35%] of 539). Using the Youden index cutoff (0·274) to classify phenotype, five (63%) of eight patients with the hyperinflammatory phenotype and 12 (39%) of 31 with the hypoinflammatory phenotype died. Compared with matched patients recruited to HARP-2, levels of IL-6 were similar in our cohort, whereas soluble TNFR1 was significantly lower in patients with COVID-19-associated ARDS.
INTERPRETATION: In this exploratory analysis of 39 patients, ARDS due to COVID-19 was not associated with higher systemic inflammation and was associated with a lower prevalence of the hyperinflammatory phenotype than that observed in historical ARDS data. This finding suggests that the excess mortality observed in COVID-19-related ARDS is unlikely to be due to the upregulation of inflammatory pathways described by the parsimonious model.
FUNDING: US National Institutes of Health, Innovate UK, and Randox.
参考来源
- Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020. PMID: 32861275. doi:10.1016/S2213-2600(20)30366-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。